Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 367

Sort by

Sort Order Select

Journal Articles

A prospective, blinded study of a PF4-dependent assay for HIT diagnosis

Bethany Samuelson Bannow, Deepti M. Warad, Curtis G. Jones, Shannon M. Pechauer, Brian R. Curtis, Daniel W. Bougie, Ruchika Sharma, Diane E. Grill, Mary W. Redman, Parisa R. Khalighi, Rachel R. Leger, Rajiv K. Pruthi, Dong Chen, Daniel E. Sabath, Richard H. Aster, David A. Garcia, Anand Padmanabhan

Blood (2021) 137 (8): 1082–1089.

https://doi.org/10.1182/blood.2020008195

Published: 2021

Includes: Supplemental data

Journal Articles

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

Stephane De Botton, Joseph M Brandwein, MD, Eytan M. Stein, MD, Andrew H. Wei, Daniela Weber, Arnaud Pigneux, Nicolas Boissel, MD PhD, Peter Paschka, MD, Konstanze Döhner, Salem Abi Nehme, Mark G. Frattini, MD, Roland Marion-Gallois, Jixian (Jason) Wang, Chris Cameron, Muhaimen Siddiqui, Rana A. Qadeer, Hartmut Döhner

Blood (2019) 134 (Supplement_1): 3893.

https://doi.org/10.1182/blood-2019-122700

Published: 2019

Journal Articles

Validation of the Plasmic Score for Predicting ADAMTS13 Activity < 10% in Patients Admitted to Hospitals in Alberta with Suspected Thrombotic Thrombocytopenic Purpura

Chris Wynick, MD MSc, BSc, Joanne Britto, MD BSc, Daniel Sawler, MD BSc, Arabesque Parker, MD, Mohammad Karkhaneh, PhD, Dawn Goodyear, MD, Haowei Linda Sun, MDFRCPC

Blood (2019) 134 (Supplement_1): 2379.

https://doi.org/10.1182/blood-2019-126354

Published: 2019

Journal Articles

Spectrum of Neurologic Complications after Allogeneic Hematopoietic Cell Transplantation for Hematologic Diseases in Adults: Systematic Review and Meta-Analysis

Maria Gavriilaki, MD, Maria Mainou, MD, Eleni Gavriilaki, MD, Anna-Bettina Haidich, Sotirios Papagiannopoulos, Ioanna Sakellari, Achilles Anagnostopoulos, Vasilis Kimiskidis

Blood (2019) 134 (Supplement_1): 5692.

https://doi.org/10.1182/blood-2019-128641

Published: 2019

Journal Articles

Outcomes of Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Meta-Analysis

Neelakanta Dadi, MDMRCP, Venkata Vosuri, MD, Samip R Master, MD, Richard Preston Mansour, MD

Blood (2019) 134 (Supplement_1): 5699.

https://doi.org/10.1182/blood-2019-130558

Published: 2019

Journal Articles

Quality-Adjusted Survival for Low-Dose Cytarabine (LDAC) Versus Glasdegib+LDAC Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Not Candidates for Intensive Chemotherapy: A Q-TWiST Analysis

Youngmin Kwon, BA, Timothy J Bell, MHA, Caitlyn Solem, PhD, Joseph C Cappelleri, PhD MPH, MS, Courtney Johnson, MPH, Helen Bhattacharyya, PhD, Caroline J. Hoang, PhD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 2610.

https://doi.org/10.1182/blood-2019-126672

Published: 2019

Journal Articles

Individualized Prediction of Follicular Lymphoma Risk Using a Combination of Blood t(14;18) Frequency Years before Diagnosis and a Polygenic Risk Score (PRS) of 9 SNPs Associated with Follicular Lymphoma Susceptibility

Herve Ghesquieres, MD PhD, Youenn Drouet, PhD, Manon Zala, Paolo Vineis, PhD, Gilles A. Salles, MD PhD, Bertrand Nadel, PhD, Sandrine Roulland, PharmD, PhD

Blood (2019) 134 (Supplement_1): 2775.

https://doi.org/10.1182/blood-2019-130618

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Cynthia Z. Qi, MBA, Bhavik J. Pandya, PharmD, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3859.

https://doi.org/10.1182/blood-2019-123819

Published: 2019

Journal Articles

Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Adam J Olszewski, MD, Thomas A Ollila, MD, John L. Reagan, MD

Blood (2019) 134 (Supplement_1): 2824.

https://doi.org/10.1182/blood-2019-121841

Published: 2019

Journal Articles

Persistent Red Blood Cell (RBC) Transfusion Is Associated with Increased Mortality Risk in Transfusion-Dependent (TD) Patients with Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS+)

Blood (2019) 134 (Supplement_1): 3012.

https://doi.org/10.1182/blood-2019-123684

Published: 2019

Journal Articles

Comparison of a New Reduced Toxicity Myeloablative Treosulfan and Fludarabine Preparative Regimen with Myeloablative Busulfan or Melphalan in Combination with Fludarabine in Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes: A Retrospective Matched Pair Analysis of Patients from a Prospective Randomized Trial and the European Blood and Marrow Transplantation Society Registry

Dietrich W. Beelen, Simona Iacobelli, Linda Koster, Dirk-Jan Eikema, Anja van Biezen, Friedrich Stoelzel, MD, Fabio Ciceri, MD, Wolfgang Bethge, Peter Dreger, Eva-Maria Wagner, Péter Reményi, Matthias Stelljes, Miroslaw Markiewicz

Blood (2019) 134 (Supplement_1): 3326.

https://doi.org/10.1182/blood-2019-127108

Published: 2019

Journal Articles

Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes

Alexandre Sostelly, M.Eng., PhD, Antoine Soubret, Christoph Bucher, MD, Simon Buatois, Jean-Eric Charoin, Gregor Jordan, Barbara Klughammer, PhD, Andreas Dieckmann, Taku Fukuzawa, PhD, Keisuke Gotanda, Kenji Shinomiya, Sung-Soo Yoon, MD PhD, Jens P. Panse, Junichi Nishimura, MD PhD, Alexander Röth, MD PhD, Zsolt Nagy, MD PhD, Régis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 1227.

https://doi.org/10.1182/blood-2019-126911

Published: 2019

Journal Articles

A Quantitative Systems Pharmacology (QSP) Model to Predict Receptor Occupancy of Bruton's Tyrosine Kinase (BTK) Inhibitors in Peripheral Blood Mononuclear Cells, Bone Marrow and Lymph Nodes of Patients with B-Cell Malignancies

Srikumar Sahasranaman, PhD, Oleg Demin, Jr., Dmitry Shchelokov, Veronika Musatova, Nageshwar Budha, PhD, Ying Ou, PhD

Blood (2019) 134 (Supplement_1): 1289.

https://doi.org/10.1182/blood-2019-129133

Published: 2019

Journal Articles

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States

Matthew S. Davids, MD, Anuja Chatterjee, MSc, Arliene Ravelo, MPH, Sheila Shapouri, PharmD, MS, Beenish S Manzoor, PhD, Kavita Sail, PhD, Gijs Van de Wetering, PhD, Michael Hallek

Blood (2019) 134 (Supplement_1): 4741.

https://doi.org/10.1182/blood-2019-123706

Published: 2019

Journal Articles

Cost-Effectiveness of Venetoclax and Rituximab Combination Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in Argentina

Jorge Federico Elgart, Economist, Mariana Glancszpigel, Economist, Diego Kanevsky, Biochemist, Maria Godar, BS, Valeria Touliet, Natalia Albaytero, Dentist

Blood (2019) 134 (Supplement_1): 2139.

https://doi.org/10.1182/blood-2019-121490

Published: 2019

Journal Articles

A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE)

Thierry Facon, MD, Jesús San-Miguel, Saad Z. Usmani, MD, Meletios A. Dimopoulos, MD, Shaji K. Kumar, MD, Maria-Victoria Mateos, Michele Cavo, Bart Heeg, PhD, Sophie Van Beekhuizen, MSc, Marta Pisini, MBA, Sandhya Nair, Annette Lam, BSc, MSc, Mary Slavcev, Jianming He, PhD

Blood (2019) 134 (Supplement_1): 2144.

https://doi.org/10.1182/blood-2019-123561

Published: 2019

Journal Articles

Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS)

Alix E. Seif, MD, Yimei Li, PhD, Viviane C. Cahen, Yuan-Shung V. Huang, MS, Matt Hall, PhD, E. Anders Kolb, MD, Brian T. Fisher, DO, MSCE, Richard Aplenc, MD PhD, Kelly D Getz

Blood (2019) 134 (Supplement_1): 3496.

https://doi.org/10.1182/blood-2019-122887

Published: 2019

Journal Articles

Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R 2 -CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study

Blood (2019) 134 (Supplement_1): 3475.

https://doi.org/10.1182/blood-2019-123948

Published: 2019

Journal Articles

Estimation of Total Costs in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Receiving Tisagenlecleucel from a US Hospital's Perspective

Hongbo Yang, Yanni Hao, PhD, Xinglei Chai, PhD, Cynthia Z. Qi, MBA, Eric Q Wu

Blood (2019) 134 (Supplement_1): 3419.

https://doi.org/10.1182/blood-2019-129070

Published: 2019

Journal Articles

Cost-Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease

Lee F. Allen, MD PhD, Kavita Aggarwal, PharmD, Michael Vredenburg, PhD, Christine Barnett, PhD, Deirdre Mladsi, BA, Ray Kim, MD

Blood (2019) 134 (Supplement_1): 3454.

https://doi.org/10.1182/blood-2019-131822

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A prospective, blinded study of a PF4-dependent assay for HIT diagnosis

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

Validation of the Plasmic Score for Predicting ADAMTS13 Activity < 10% in Patients Admitted to Hospitals in Alberta with Suspected Thrombotic Thrombocytopenic Purpura

Spectrum of Neurologic Complications after Allogeneic Hematopoietic Cell Transplantation for Hematologic Diseases in Adults: Systematic Review and Meta-Analysis

Outcomes of Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Meta-Analysis

Quality-Adjusted Survival for Low-Dose Cytarabine (LDAC) Versus Glasdegib+LDAC Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Not Candidates for Intensive Chemotherapy: A Q-TWiST Analysis

Individualized Prediction of Follicular Lymphoma Risk Using a Combination of Blood t(14;18) Frequency Years before Diagnosis and a Polygenic Risk Score (PRS) of 9 SNPs Associated with Follicular Lymphoma Susceptibility

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Persistent Red Blood Cell (RBC) Transfusion Is Associated with Increased Mortality Risk in Transfusion-Dependent (TD) Patients with Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS+)

Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes

A Quantitative Systems Pharmacology (QSP) Model to Predict Receptor Occupancy of Bruton's Tyrosine Kinase (BTK) Inhibitors in Peripheral Blood Mononuclear Cells, Bone Marrow and Lymph Nodes of Patients with B-Cell Malignancies

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States

Cost-Effectiveness of Venetoclax and Rituximab Combination Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in Argentina

A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE)

Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS)

Estimation of Total Costs in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Receiving Tisagenlecleucel from a US Hospital's Perspective

Cost-Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only